These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36511818)

  • 1. The Value of Scientific Publications in Surgical Device Innovation.
    Song A; Rensi SE; Tarquinio AG; Cahan E; de Ruijter VE; Wall JK
    Surg Innov; 2023 Oct; 30(5):615-621. PubMed ID: 36511818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venture capital investment in urology, 2011 to mid-2021.
    Briggs LG; Uppal N; Langbein B; Bhojani N; Kathrins M; Trinh QD
    Can J Urol; 2023 Oct; 30(5):11659-11667. PubMed ID: 37838992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic management and organizational culture of medical device companies in relation to corporate performance.
    Park S; Kim HK; Lee HJ; Choi M; Lee M; Jakovljevic M
    J Med Econ; 2023; 26(1):781-792. PubMed ID: 37300440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.
    Lee SJ; Cho L; Klang E; Wall J; Rensi S; Glicksberg BS
    JAMA Netw Open; 2021 Jun; 4(6):e2112562. PubMed ID: 34156454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
    Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
    BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anatomy of medical research: US and international comparisons.
    Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
    JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How much do physician-entrepreneurs contribute to new medical devices?
    Smith SW; Sfekas A
    Med Care; 2013 May; 51(5):461-7. PubMed ID: 23358387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market entry and exit by biotech and device companies funded by venture capital.
    Burns LR; Housman MG; Robinson CA
    Health Aff (Millwood); 2009; 28(1):w76-86. PubMed ID: 19049998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orthopaedic Device Approval Through the Premarket Approval Process: A Financial Feasibility Analysis for a Single Center.
    Yang BW; Iorio ML; Day CS
    J Bone Joint Surg Am; 2017 Mar; 99(6):e26. PubMed ID: 28291189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital Behavior Change Interventions for the Prevention and Management of Type 2 Diabetes: Systematic Market Analysis.
    Keller R; Hartmann S; Teepe GW; Lohse KM; Alattas A; Tudor Car L; Müller-Riemenschneider F; von Wangenheim F; Mair JL; Kowatsch T
    J Med Internet Res; 2022 Jan; 24(1):e33348. PubMed ID: 34994693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Clinical Robustness of Digital Health Startups: Cross-sectional Observational Analysis.
    Day S; Shah V; Kaganoff S; Powelson S; Mathews SC
    J Med Internet Res; 2022 Jun; 24(6):e37677. PubMed ID: 35723914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.